celgosivir has been researched along with castanospermine in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Behnam, MA; Boldescu, V; Klein, CD; Nitsche, C | 1 |
| Bowlin, TL; Kang, MS; Liu, PS; Sunkara, PS; Taylor, DL; Tyms, AS | 1 |
| Ahmed, SP; Bridges, CG; Kang, MS; Nash, RJ; Porter, EA; Taylor, DL; Tyms, AS | 1 |
| Brennan, TM; Bridges, CG; Kang, MS; Sunkara, PS; Taylor, DL; Tyms, AS | 1 |
| Torres, G | 1 |
| Connolly, J; Khoo, YM; Lee, HS; Low, J; Lu, F; Ooi, EE; Rathore, AP; Sung, C; Vasudevan, SG; Watanabe, S | 1 |
| Aw, P; Chan, KW; Choy, MM; Connolly, JE; de Sessions, PF; Fan, L; Hibberd, ML; Kamaraj, US; Khoo, YM; Lee, B; Lee, HS; Low, JG; Ooi, EE; Rathore, AP; Sessions, OM; Sung, C; Vasudevan, SG; Vijaykrishna, D; Watanabe, S; Wei, Y; Wijaya, L | 1 |
| Bradfute, SB; Clarke, EC; Nofchissey, RA; Ye, C | 1 |
1 review(s) available for celgosivir and castanospermine
| Article | Year |
|---|---|
The Medicinal Chemistry of Dengue Virus.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; Dengue; Dengue Virus; Humans; Molecular Conformation; Structure-Activity Relationship | 2016 |
2 trial(s) available for celgosivir and castanospermine
| Article | Year |
|---|---|
BUCAST: another new antiviral.
Topics: Animals; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Glycoside Hydrolases; HIV; Humans; Indolizines; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 1995 |
Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients.
Topics: Adult; Antiviral Agents; Cytokines; Dengue; Dengue Virus; Female; Half-Life; High-Throughput Nucleotide Sequencing; Humans; Indolizines; Male; Phylogeny; Th1 Cells; Viral Load; Viremia; Virus Replication | 2016 |
5 other study(ies) available for celgosivir and castanospermine
| Article | Year |
|---|---|
6-0-butanoylcastanospermine (MDL 28,574) inhibits glycoprotein processing and the growth of HIVs.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Cell Line; Cell Line, Transformed; Dose-Response Relationship, Drug; Gene Products, env; Glucosamine; Glycoside Hydrolase Inhibitors; HIV Envelope Protein gp120; HIV Envelope Protein gp160; HIV-1; Humans; Indolizines; Mice; Moloney murine leukemia virus; Protein Precursors; Viral Plaque Assay; Zalcitabine | 1991 |
Antiviral activity and metabolism of the castanospermine derivative MDL 28,574, in cells infected with herpes simplex virus type 2.
Topics: Animals; Antiviral Agents; Carbon Radioisotopes; Cells, Cultured; Chlorocebus aethiops; Embryo, Mammalian; Fibroblasts; Gas Chromatography-Mass Spectrometry; Glucosidases; Glycoproteins; Herpesvirus 2, Human; Humans; Indolizines; Vero Cells; Viral Plaque Assay | 1995 |
Inhibition of alpha-glucosidase I of the glycoprotein-processing enzymes by 6-O-butanoyl castanospermine (MDL 28,574) and its consequences in human immunodeficiency virus-infected T cells.
Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; Cell Line; Glycoproteins; Glycoside Hydrolase Inhibitors; HIV Envelope Protein gp120; HIV-1; Humans; Indolizines; T-Lymphocytes | 1994 |
Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial.
Topics: Animals; Antiviral Agents; Dengue; Dengue Virus; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy; Indolizines; Mice; Survival Analysis | 2012 |
The iminosugars celgosivir, castanospermine and UV-4 inhibit SARS-CoV-2 replication.
Topics: 1-Deoxynojirimycin; Animals; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Glycoside Hydrolase Inhibitors; Humans; Indolizines; SARS-CoV-2; Vero Cells; Virus Replication | 2021 |